公开(公告)号：US20230248683A1

公开(公告)日：2023-08-10

申请号：US18300924

申请日：2023-04-14

Applicant: Kura Oncology, Inc.

Inventor： Francis Burrows ,  Yi Liu

IPC: A61K31/223 ,  A61P35/00 ,  A61K33/243 ,  A61K31/045 ,  A61K31/365 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K31/223 ,  A61P35/00 ,  A61K33/243 ,  A61K31/045 ,  A61K31/365 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61K39/3955 ,  A61K45/06

Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.

公开(公告)号：US11673898B2

公开(公告)日：2023-06-13

申请号：US16944040

申请日：2020-07-30

Applicant: Kura Oncology, Inc. ,  The Regents of The University of Michigan

Inventor： Tao Wu ,  Liansheng Li ,  Yi Wang ,  Pingda Ren ,  Jolanta Grembecka ,  Tomasz Cierpicki ,  Szymon Klossowski ,  Jonathan Pollock ,  Dmitry Borkin

IPC: C07D495/04 ,  A61P35/00

CPC classification number: C07D495/04 ,  A61P35/00

Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.

公开(公告)号：US11649251B2

公开(公告)日：2023-05-16

申请号：US16647855

申请日：2018-09-19

Applicant: Kura Oncology, Inc.

Inventor： Tao Wu ,  Liansheng Li ,  Pingda Ren

IPC: C07D495/04 ,  A61K31/519 ,  C07D519/00 ,  A61P35/00 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  A61K9/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  A61K9/0019 ,  A61K9/0053

Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

公开(公告)号：US20230089412A1

公开(公告)日：2023-03-23

申请号：US17829183

申请日：2022-05-31

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto ,  Catherine Rose Scholz

IPC: A61K31/4709 ,  C12Q1/6886 ,  A61K45/06

Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.

公开(公告)号：US20220305001A1

公开(公告)日：2022-09-29

申请号：US17608086

申请日：2020-05-01

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto

IPC: A61K31/4709 ,  A61P35/02 ,  A61K47/00

Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Acute Myeloid Leukemia in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of FLT3LG.

公开(公告)号：US20220168296A1

公开(公告)日：2022-06-02

申请号：US17599937

申请日：2020-03-26

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto

IPC: A61K31/4709 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, Diffuse Large B Cell Lymphoma (“DLBCL”) and/or Mycosis Fungoides (“MF”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

公开(公告)号：US11207314B2

公开(公告)日：2021-12-28

申请号：US16007931

申请日：2018-06-13

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto ,  Catherine Rose Scholz

IPC: A61K31/4709 ,  C12Q1/6886 ,  A61K45/06

Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.

公开(公告)号：US10980793B2

公开(公告)日：2021-04-20

申请号：US16541063

申请日：2019-08-14

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto ,  Catherine Rose Scholz

IPC: A61K31/4709 ,  A61K45/06

Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

公开(公告)号：US10426767B2

公开(公告)日：2019-10-01

申请号：US15946578

申请日：2018-04-05

Applicant: Kura Oncology, Inc.

Inventor： Antonio Gualberto ,  Catherine Rose Scholz

IPC: A61K31/4709 ,  A61K31/06 ,  A61K45/06

Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

公开(公告)号：US20190192517A1

公开(公告)日：2019-06-27

申请号：US16222398

申请日：2018-12-17

Applicant: Kura Oncology, Inc.

Inventor： Francis Burrows ,  Dana Hu-Lowe ,  Linda Kessler

IPC: A61K31/517 ,  C12Q1/6886 ,  C12Q1/6827 ,  C12Q1/6851 ,  C12Q1/686 ,  A61P35/00

CPC classification number: A61K31/517 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6827 ,  C12Q1/6851 ,  C12Q1/686 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/48

Abstract: The present disclosure provides methods and systems for identifying and/or treating subjects having cancer, such as squamous cell carcinoma, who are more likely to respond to treatment with an ERK inhibitor.